白藜芦醇对非酒精性脂肪性肝炎大鼠肝组织SIRT3表达的影响*

doi:10.3969/j.issn.1672-5069.2017.04.006

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (4): 402-407.doi: 10.3969/j.issn.1672-5069.2017.04.006

白藜芦醇对非酒精性脂肪性肝炎大鼠肝组织SIRT3表达的影响^*

陈娟, 孔维宗, 梁凯, 王迎春

116001辽宁省大连市大连大学（陈娟,梁凯）; 附属中山医院消化内科（孔维宗,王迎春）

收稿日期:2016-10-26 出版日期:2017-07-10 发布日期:2017-07-07
通讯作者: 王迎春，E-mail:wych_1648@126.com
作者简介:陈娟，女，27岁，硕士研究生。主要从事非酒精性脂肪性肝病防治研究。E-mail：chj_0130@163.com
基金资助:
大连市医学卫生科学研究计划项目（编号：2016142）

Improved expression of SIRT3 in liver tissues by resveratrol in rats with nonalcoholic steatohepatitis

Chen Juan, Kong Weizong, Liang Kai, et al.

Department of Gastroenterology,Zhongshan Hospital,Affiliated to Dalian University,Dalian 116001,Liaoning Province,China

Received:2016-10-26 Online:2017-07-10 Published:2017-07-07

摘要/Abstract

摘要： 目的研究非酒精性脂肪性肝炎(NASH)大鼠肝组织沉默交配型信息调节因子2同源蛋白3（SIRT3）的表达变化,探讨其在NASH发病中的作用及白藜芦醇对其的影响。方法 60只SD大鼠被随机分为正常对照组、NASH模型组和白藜芦醇处理组,每组20只。采用高脂饲料喂养建立NASH大鼠模型。制备新鲜肝组织匀浆,检测肝组织内活性氧（ROS）含量和超氧化物歧化酶（SOD）活性。常规检查肝组织病理学变化和超微结构的变化。采用免疫组化法分析SIRT3蛋白的亚细胞定位,采用Western Blot定量检测SIRT3蛋白的表达。结果模型组大鼠肝指数、血清ALT、AST、TG、TC、LDL-C含量和氧化应激水平显著高于对照组（P<0.01）,药物处理组显著低于模型组（P<0.01）;模型组大鼠非酒精性脂肪性肝病活动性评分（NAS）为（6.83±0.41）分,显著高于对照组[（0.24±0.08）分,P<0.01],处理组为（3.27±0.29）分,显著低于模型组（P<0.01）;模型组大鼠肝细胞线粒体半定量评分为（3.24±0.21）分,显著高于对照组[（0.17±0.03）分,P<0.01],处理组为（1.39±0.12）分,显著低于模型组（P<0.01）;免疫组化检测显示SIRT3蛋白在细胞核和细胞质中均有表达,模型组SIRT3蛋白相对表达量为（0.24±0.03）,显著低于对照组[（0.58±0.02）,P<0.01],而处理组为（0.46±0.03）,显著高于模型组（P<0.01）。结论 NASH大鼠肝组织SIRT3表达量下降,白藜芦醇干预可通过上调SIRT3的表达改善NASH病理学变化。

关键词: 非酒精性脂肪性肝炎, SIRT3, 白藜芦醇, 大鼠

Abstract: Objective To study the expression and effect of silent mating type information regulation 2 homolog 3（SIRT3） in rats with nonalcoholic steatohepatitis（NASH） and evaluate the beneficial intervention of resveratrol on it. Methods The 60 rats were randomly divided into three groups（20 in each）,e.g. normal,NASH and resveratrol-intervened groups. At the end of 24th week,all the rats were sacrificed. Serum biochemical parameters and liver histological ultrastructural characteristics were observed. Reactive oxygen species（ROS） and superoxide dismutase（SOD） in the liver tissues were determined,and SIRT3 protein was assayed by immunohistochemical staining and Western blot. Results The liver index,serum ALT,AST,TG,TC,LDL-C and oxidative stress levels in model rats were significantly higher than those in the normal control（P<0.01）,and all those indicators in resveratrol-intervened group showed significantly lower than in the model group（P<0.01）;the nonalcoholic fatty liver disease activity score（NAS） in model group was （6.83±0.41）,significantly higher than that in the normal group [（0.24±0.08）,P<0.01],and in the treatment group was（3.27±0.29）,significantly lower than in the model group （P<0.01）;the Flameng semiquantitative score of hepatic mitochondria in the model group was （3.24±0.21）,significantly higher than that in the normal group [（0.17±0.03）,P<0.01],and in the treatment group was（1.39±0.12）,significantly lower than that in the model group（P<0.01）;immunohistochemical staining showed that SIRT3 protein appeared both in the cell nucleus and cytoplasm,and the Western blot quantitative detection of SIRT3 protein showed that it was（0.24±0.03） in the model group,significantly lower than that in the normal group[（0.58±0.02）,P<0.01],and in the treatment group was （0.46±0.03）,significantly higher than that in the model group （P<0.01）. Conclusion The SIRT3 expression is decreased in liver tissues of rats with NASH,and resveratrol intervention can improve the expression of the protein,which might alleviate NASH.

Key words: Nonalcoholic steatohepatitis, Silent mating type information regulation 2 homolog 3, Resveratrol, Rats

陈娟, 孔维宗, 梁凯, 王迎春. 白藜芦醇对非酒精性脂肪性肝炎大鼠肝组织SIRT3表达的影响^*[J]. 实用肝脏病杂志, 2017, 20(4): 402-407.

Chen Juan, Kong Weizong, Liang Kai, et al.. Improved expression of SIRT3 in liver tissues by resveratrol in rats with nonalcoholic steatohepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 402-407.

参考文献

[1] Cohen JC,Horton JD,Hobbs HH. Human fatty liver disease,old questions and new insights. Science,2011,332 （6037）:1519-1523.
[2] 中华医学会. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18（3）：163-170.
[3] 谭彦芳,赵彩彦. 非酒精性脂肪性肝病药物治疗进展. 实用肝脏病杂志,2013,16（4）:378-381.
[4] 马振增,陆伦根. 非酒精性脂肪性肝病与肝硬化. 实用肝脏病杂志,2016,19（2）：135-138.
[5] Bellizzi D,Dato S,Cavalcante P,et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics,2007,89（1）:143-150.
[6] Hirschey MD,Shimazu T,Goetzman E,et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.Nature,2010,464 （7285）:121-125.
[7] Bause AS,Haigis MC. SIRT3 regulation of mitochondrial oxidative stress. Exp Gerontol,2013,48 （7）:634-639.
[8] 尹力,叶雪瑞,刘新新,等. Sirt3对过氧化氢诱导的骨髓间充质干细胞凋亡的保护作用.现代生物医学进展,2015,15（31）：6039-6042.
[9] 殷玥,李晨,余露,等. 有氧间歇训练抑制高脂喂养小鼠海马神经元损伤. 中华神经外科疾病研究杂志,2016,15（3）：213-216.
[10] Cho EH. SIRT3 as a regulator of non-alcoholic fatty liver disease.J Lifestyle Med,2014,4 （2）:80-85.
[11] 李燕强,华伟娜,杨俊霞,等. 白藜芦醇对肝脂肪积累的抑制作用及其分子机制.中国医药导报,2012,9（33）：9-11.
[12] Kleiner DE,Brunt EM,Van Natta M,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41（6）:1313-1321.
[13] FlamengW,Andres J,Ferdinande P,et a1. Mitochondrial function in myocardial stunning. J Mol Cell Cardiol,1991,23:1-11.
[14] Michan S,Sinclair D. Sirtuins in mammals:insights into their biological function.Biochem J,2007,404 （1）:1-13.
[15] Park J,Chen Y,Tishkoff DX,et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell,2013,50（6）:919-930.
[16] Zhang D,Liu ZX,Choi CS,et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci U S A,2007,104（43）:17075-17080.
[17] Hirschey MD,Shimazu T,Jing E,et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell,2011,44（2）:177-190.
[18] Shi T,Fan GQ,Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells.J Dig Dis,2010,11（1）:55-62.
[19] Onyango P,Celic I,McCaffery JM,et al. SIRT3,a human SIR2 homologue,is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A,2002,99（21）:13653-13658.
[20] Cooper HM,Spelbrink JN. The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem J,2008,411（2）:279-285.
[21] Sundaresan NR,Samant SA,Pillai VB,et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70.Mol Cell Biol,2008,28（20）:6384-6401.

白藜芦醇对非酒精性脂肪性肝炎大鼠肝组织SIRT3表达的影响^*

Improved expression of SIRT3 in liver tissues by resveratrol in rats with nonalcoholic steatohepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[2]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[3]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[4]	石小龙, 杜睿, 秦革萍, 薛华燕, 张宏鑫. 七氟醚对脓毒症大鼠肝损伤的保护作用及其作用机制研究*[J]. 实用肝脏病杂志, 2019, 22(5): 640-643.
[5]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[6]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[9]	郭丽平, 张成宏, 宁宝烁, 许敏, 徐贝贝, 王雪, 李异玲. 一种新生大鼠肝细胞分离改良方法的建立^*[J]. 实用肝脏病杂志, 2019, 22(1): 17-20.
[10]	玉苏甫·吐尔逊, 赵燕霞. 小剂量二乙基亚硝胺诱导大鼠肝纤维化模型的建立[J]. 实用肝脏病杂志, 2019, 22(1): 33-36.
[11]	麦静愔, 陈天阳, 平键, 成扬, 陈建杰. MiR-384对HFFA诱导的Hepa1-6细胞sirt3/FOXO1信号通路的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 829-832.
[12]	刘恩强, 陈果, 廖修用, 许美凤, 魏贵玉, 罗小平. 虾青素对肝纤维化大鼠的保护作用及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 842-846.
[13]	隋菱, 杜纪坤, 郑静彬, 蔡国弟, 李莉. 姜黄素对CCl₄所致急性肝损伤大鼠的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 709-712.
[14]	李梦婷, 李兵航, 周达, 丁永年, 陈源文, 范建高. 非酒精性脂肪性肝病小鼠肝组织脯氨酰内肽酶蛋白及其活性变化^*[J]. 实用肝脏病杂志, 2018, 21(4): 549-552.
[15]	高翔, 尚双艳. 复方鳖甲软肝片对二乙基亚硝胺所致原发性肝癌大鼠肝组织PCNA和α-SMA表达的影响^*[J]. 实用肝脏病杂志, 2018, 21(4): 553-556.